PF4 and B-cell chronic lymphocytic leukemia: In contrast, ibrutinib-treated CLL patients showed an inhibitory trend of PF4 secretion in response to bacteria, IV.3-xl and CRP-xl, with the latter two being significantly reduced compared to untreated CLL platelets (Figure 1B).